REGULATORY

Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo

May 28, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) should discuss the rollout of cost-effective assessments in Japan by taking due account of associated financial and personnel burdens placed on companies, a drug maker official said on May 27. “We’d like you…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015
HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015

REGULATORY

Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
LDP Health Panel Approves Health Insurance Bill with OTC-Like Drug Charges
March 5, 2026
Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…